Xencor Inc
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- XNCRXencor, Inc.10Calm
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
FinishedPhase 272 patientsMain results: Jun 10, 2025 - XNCRXencor, Inc.10Calm
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Running, no new patientsPhase 2170 patientsMain results: Oct 15, 2025
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
5 sales (0 not pre-planned) · 0 purchases
- Feigal EllenBoard member · Jun 18, 2026Sold 6,843 sharesabout $89 thousand · pre-planned
- GORMAN KEVIN CHARLESBoard member · Jun 15, 2026Sold 7,527 sharesabout $93 thousand · pre-planned
- GUSTAFSON KURT ABoard member · Jun 15, 2026Sold 5,474 sharesabout $67 thousand · pre-planned
- RANIERI RICHARD JBoard member · Jun 15, 2026Sold 5,474 sharesabout $67 thousand · pre-planned
- Montgomery Alan BruceBoard member · Jun 15, 2026Sold 5,064 sharesabout $62 thousand · pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Quarterly reportQuarterly report (10-Q)Nov 4, 2026
- Shared quarterly resultsNews report (8-K)Nov 4, 2026
- Shared quarterly results; Shared information with investors; Other newsNews report (8-K)Oct 26, 2026
- Quarterly reportQuarterly report (10-Q)Aug 5, 2026
- Shared quarterly resultsNews report (8-K)Aug 5, 2026